Processa Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Processa Pharmaceuticals

13/05/2024 13:21

* Processa Pharmaceuticals Inc  PCSA.OQ  reported a
quarterly
adjusted loss of $1.11​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-3.60.  The lone analyst forecast for the
quarter was for a loss of $1.18 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Processa Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $1.11​.
    * The company reported a quarterly loss of $2.73 million.
    * Processa Pharmaceuticals Inc shares had fallen by 11.6%
this
quarter and lost 68.8% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Processa
Pharmaceuticals Inc is $44.00 
This summary was machine generated from LSEG data May 13 at
12:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.18          -1.11          Beat
 Dec. 31 2023      -1.60          -1.70          Missed
 Sep. 30 2023      -2.00          -1.60          Beat